Cancer-drug makers consider price caps to avoid feared backlash

05/10/2006 | Wall Street Journal, The

Some drugmakers are considering cost containment measures for high-priced cancer drugs as they weigh the impact of a pending public relations crisis. Bristol-Myers Squibb and ImClone Systems, for example, are considering a cap for their Erbitux if sales of the expensive cancer drug expand, and other drugmakers who foresee a pricing backlash are considering similar changes.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Actuary
Meridian Health Plan
Detroit, MI
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC